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Francisella tularensis is the causative agent of a spectrum of diseases collectively known as 
tularemia. The extreme virulence of the pathogen in humans, combined with the low infectious 
dose and the ease of dissemination by aerosol have led to concerns about its abuse as a 
bioweapon. Until recently, nothing was known about the virulence mechanisms and even now, 
there is still a relatively poor understanding of pathogen virulence. Completion of increasing 
numbers of Francisella genome sequences, combined with comparative genomics and 
proteomics studies, are contributing to the knowledge in this area. Tularemia may be treated 
with antibiotics, but there is currently no licensed vaccine. An attenuated strain, the Live 
Vaccine Strain (LVS) has been used to vaccinate military and at risk laboratory personnel, but 
safety concerns mean that it is unlikely to be licensed by the FDA for general use. Little is 
known about the protective immunity induced by vaccination with LVS, in humans or animal 
models. Immunoproteomics studies with sera from infected humans or vaccinated mouse 
strains, are being used in gel-based or proteome microarray approaches to give insight into 
the humoral immune response. In addition, these data have the potential to be exploited in 
the identification of new diagnostic or protective antigens, the design of next generation live 
vaccine strains, and the development of subunit vaccines. Herein, we briefly review the current 
knowledge from Francisella comparative proteomics studies and then focus upon the findings 
from immunoproteomics approaches.
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regarding residual virulence. In addition, the lack of knowledge of 
the attenuating mutations and mechanisms of protection means 
that LVS is unlikely to be licensed for use in the general population 
in the near future. Despite these concerns, LVS remains the gold 
standard against which new tularemia vaccine candidates will be 
judged. LVS is also currently the only tularemia vaccine candidate 
to have been evaluated and shown to be effective in humans, and 
after the terrorist attacks of 2001, there has been renewed interest 
in improving the manufacturing and testing of LVS (Pasetti et al., 
2008). In addition, LVS remains virulent in animals, making it 
an attractive surrogate for virulent strains of the pathogen, which 
require use of specialized containment facilities.
Despite the recent surge of interest in F. tularensis, there remain 
many unknowns, for example in the mechanisms of pathogen viru-
lence or the host immune response. The prevailing dogma is that 
humoral immunity plays a critical role in defense against extracel-
lular pathogens, whilst cell-mediated immunity is more impor-
tant for clearance of intracellular pathogens, such as F. tularensis. 
It is unclear whether this is true for Francisella, and whether the 
roles of the immune system are different for type A and B strains. 
Recent studies have confirmed the role of cell-mediated immu-
nity in protection against tularemia, and in addition the impor-
tance of humoral immunity is also now recognized (reviewed in 
Kirimanjeswara et al., 2008). Many laboratories have reported that 
a robust anti-Francisella antibody response is generated in humans 
within 2 weeks of LVS vaccination or actual infection (Koskela 
and Herva, 1982; Koskela and Salminen, 1985; Tarnvik, 1989; 
IntroductIon
The intracellular pathogen, Francisella tularensis, is the etiologi-
cal agent of tularemia in humans and animals. It is increasingly 
being isolated in the United States and several European coun-
tries (Eliasson et al., 2006; Vorou et al., 2007), although humans 
are an accidental host. The genus Francisella contains the species 
F. tularensis, F. novicida, and F. philomiragia. F. tularensis is further 
subdivided into three subspecies: F. tularensis subspecies tularensis 
(type A), F. tularensis subspecies holarctica (type B), and F. tularen-
sis subspecies mediaasiatica (Sjostedt, 2001). Strains of subspecies 
tularensis and holarctica are primarily responsible for human dis-
ease, whilst F. philomiragia and F. novicida are avirulent in healthy 
humans. F. tularensis subsp. mediaasiatica is a restricted entity with 
unique biochemical characteristics that has only been isolated in 
Kazakhstan and Turkmenistan in Central Asia and exhibits viru-
lence in rabbits similar to Type B strains. In recent years, F. tularensis 
has gained significant attention as one of six organisms designated 
as high priority agents that could be exploited as agents of bioter-
ror (category A pathogens) by the US Center for Disease Control 
and Prevention. Combined, the low infectious dose and ease of 
dissemination of type A F. tularensis have made it a threat to both 
military personnel and civilians alike (Dennis et al., 2001).
There is currently no licensed vaccine available in North America, 
although an attenuated type B strain, known as the Live Vaccine 
Strain (LVS), has been used to vaccinate military personnel and 
laboratory workers. This strain was derived from a Soviet strain in 
the 1960s and was not rationally attenuated, leading to concerns 
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Waag et al., 1995; Janovska et al., 2007b), but the role of these 
 antibodies in protective immunity remains unclear. A review of 
host immunity toward F. tularensis described the current knowledge 
in more depth and suggests that a synergy between humoral and 
cell-mediated immunity is required to induce effective protection 
(Kirimanjeswara et al., 2008). If either LVS is to be licensed, or 
next generation tularemia vaccines are to be successfully developed, 
there needs to be an understanding of the immune mechanisms in 
the host that need to be activated to induce protective immunity. 
This in turn requires a fundamental understanding of the mecha-
nisms of virulence of F. tularensis.
For many years knowledge of Francisella virulence factors has 
been lacking, with no classical bacterial virulence factors hav-
ing been identified. Despite a marked increase in the intensity of 
research surrounding Francisella, there is still not a complete expla-
nation of how the pathogen can disseminate and proliferate so read-
ily in the mammalian host. The completion of increasing numbers 
of Francisella genome sequences, commencing with that of strain 
SCHU S4 (Karlsson et al., 2000; Prior et al., 2001; Larsson et al., 
2005), has propelled comparative Francisella genomics (Samrakandi 
et al., 2004; Rohmer et al., 2006, 2007; Champion et al., 2009) 
and proteomics studies (Hubalek et al., 2004; Twine et al., 2005a; 
Pavkova et al., 2006) toward identification of putative virulence 
genes and proteins. Genome comparisons (reviewed in Titball and 
Petrosino, 2007) have aided in the mapping of Francisella evolution 
and adaptation to different environmental niches (Karlsson et al., 
2000; Prior et al., 2001; Larsson et al., 2005), whilst comparisons 
of the proteomes of in vitro grown strains of Francisella differing 
in virulence have revealed both similarities and differences in the 
profile of expressed proteins (Hubalek et al., 2004; Twine et al., 
2005a; Pavkova et al., 2006). Such differences may shed light upon 
the molecular mechanisms of the marked virulence differences 
between the subspecies.
Proteomics studies have also extended to the characterization 
of the repertoire of proteins reactive with sera from convalescent 
or vaccinated subjects. The broad study of large sets of proteins 
involved in the host immune response has been termed “immuno-
proteomics,” and provides information regarding Francisella immu-
nodominant antigens. This is increasing knowledge of Francisella 
proteins that stimulate the immune system, which can then be 
used in the development of subunit vaccines and diagnostics, in 
addition to determining potential correlates of protection. Given 
the relative rarity of human cases of tularemia, many of the stud-
ies of the host response to vaccination or infection with tularemia 
have been carried out in animal models of tularemia. The murine 
model of tularemia is widely used (animal models of tularemia 
were recently reviewed in Rick and Wu, 2007). Animal studies in 
the past and more recently have used rabbits (Larson, 1946; Bell 
et al., 1955; Skrodzki, 1961), rats (Downs and Coriell, 1947; Downs 
et al., 1949; Raymond and Conlan, 2009; Wu et al., 2009; Ray et al., 
2010), guinea pigs (Bell et al., 1955; Eigelsbach and Downs, 1961; 
Eigelsbach et al., 1961), and non-human primates (Eigelsbach et al., 
1962; Nelson et al., 2010).
In this article we briefly give an overview of comparative studies 
of Francisella proteomes, approaches used to study the immuno-
proteome of Francisella, and the characteristics of the reported 
immunoreactive proteins.
the Francisella proteome
comparatIve proteomIcs of Francisella
Comparative genomics studies and molecular typing methods 
provide evidence that F. novicida, could be the common ances-
tor of F. tularensis subspecies holarctica, subspecies mediaasiatica 
and subspecies tularensis (Svensson et al., 2005). Type A strains 
have recently been further divided into type AI and AII, based 
largely on their geographical distribution (Svensson et al., 2005; 
Staples et al., 2006) and have been shown to differ in virulence in 
the mouse model of tularemia (Twine et al., 2006c; Molins et al., 
2010). Genomic comparisons have allowed advances in explain-
ing the differing virulence and infectivity of the four F. tularensis 
subspecies, but are insufficient to offer a complete understanding. 
Thus, proteomics studies have also been carried out, comparing the 
in vitro protein expression profiles of all four subspecies in hopes of 
addressing the differences in virulence that genomic studies alone, 
cannot (Hubalek et al., 2004; Pavkova et al., 2006).
The results of such studies have shown that very few differences 
exist at the proteome level between strains within the same subspe-
cies, but a much greater number of differences were observed in 
proteome maps comparing the subspecies (Hubalek et al., 2004). 
The authors concluded that the proteomes of strains from subspe-
cies tularensis and mediaasiatica showed greater similarity to one 
another than to the proteomes of strains from subspecies holarctica 
(Hubalek et al., 2004; Pavkova et al., 2006). The variations observed 
included differences in protein abundance, as well as the apparent 
presence and absence of specific proteins. Charge variants of cer-
tain proteins may account for some of the detected differences in 
protein abundance between subspecies, but it is also thought that 
the amount and method of gene expression and regulation may 
vary between subspecies of F. tularensis.
Species novicida and mediaasiatica are essentially avirulent 
in humans, therefore, of particular interest are proteins that are 
uniquely expressed, or up-regulated in both subspecies tularensis 
and holarctica, but not in novicida or mediaasiatica. Such differences 
in the proteomes of these subspecies may provide insight into the 
mechanisms used by virulent subspecies of F. tularensis. Using two-
dimensional electrophoresis (2DE), Hubalek et al. (2004) compared 
the proteomes of representative strains of subspecies tularensis, 
holarctica, and mediaasiatica and identified 27 proteins that were 
either unique to, or produced in at least a twofold greater abundance 
in subspecies tularensis. These proteins are listed in Table 1, and 
the similarities and differences summarized in Figure 1. Seventeen 
of these proteins, included in Table 1, were found to have charge 
or mass variants present in the less virulent subspecies, possibly as 
a result of strain specific amino acid substitutions, or differences 
in the post-translational modification of the proteins in question 
(Hubalek et al., 2004). An additional nine proteins; signal recog-
nition particle receptor FtsY (FTT_0120), ribosomal protein L10 
(FTT_0142), 50S ribosomal protein L23 (FTT_0327), B-lactamase 
precursor (FTT_0611/0681), thymidylate synthase (FTT_1229), 
fructose bis-phosphate aldolase (FTT_1365), phosphoglycerate 
kinase (FTT_1367), transketolase I (FTT_1369), ClpB protein 
(FTT_1769), also shown in Table 1, were reported to be produced 
with at least twofold greater abundance in subspecies tularensis 
when compared to either mediaasiatica or holarctica. Heat shock 
protein ClpB has been shown to play a vital role in the multiplication 
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Table 1 | Proteins observed at higher levels, or only at detectable levels in subspecies tularensis.
Accession  
number
Protein name Profile in subsp.  
tularensis
Immunoreactive  
in convalescent/
immune sera
Reference
FTT_0018 Secretion protein Unique Human Pavkova et al. (2006)
FTT_0075 Succinate dehydrogenase iron-sulfur subunit Charge variant Mouse Hubalek et al. (2004)
FTT_0120 Signal recognition particle receptor FtsY Increased expression No Hubalek et al. (2004)
FTT_0142 Ribosomal protein L10 Increased expression No Hubalek et al. (2004)
FTT_0316 Ribosome recycling-factor Charge variant No Hubalek et al. (2004)
FTT_0327 50S ribosomal protein L23 Increased expression No Hubalek et al. (2004)
FTT_0336 50S ribosomal protein L24 Charge variant No Hubalek et al. (2004)
FTT_0371 Conserved hypothetical protein Unique No Hubalek et al. (2004)
FTT_0373c Nucleoside diphosphate kinase Charge variant Hubalek et al. (2004)
FTT_0389 NAD-specific glutamate dehydrogenase Increased expression No Pavkova et al. (2006)
FTT_0435 Putative carbon–nitrogen hydrolase Unique No Hubalek et al. (2004)
FTT_0607 4-Hydroxy-3-methylbut-2-en-1-yl diphosphate synthase Unique No Hubalek et al. (2004)
FTT_0611/0681 B-lactamase precursor Increased expression No Hubalek et al. (2004)
FTT_0613 15.7 kDa putative exported protein Unique No Hubalek et al. (2004)
FTT_0896 Phosphoribosylaminoimidazole carboxylase, catalytic  
subunit
Charge variant No Hubalek et al. (2004)
FTT_0903 Hypothetical protein Unique No Pavkova et al. (2006)
FTT_1043 FKBP-type peptidyl-prolyl cis–trans isomerase  
family protein
Increased expression Mouse Pavkova et al. (2006)
FTT_1157c Type IV pili lipoprotein (PilP) Unique No Hubalek et al. (2004), 
Pavkova et al. (2006)
FTT_1181c γ-Glutamyltranspeptidase Charge variant No Hubalek et al. (2004)
FTT_1229 Thymidylate synthase Increased expression No Hubalek et al. (2004)
FTT_1241 Serine hydroxymethyltransferase Charge variant No Hubalek et al. (2004)
FTT_1260 Hypothetical protein Unique No Pavkova et al. (2006)
FTT_1346/1701 Hypothetical protein Increased expression No Pavkova et al. (2006)
FTT_1357c Intracellular growth locus, subunit C Charge variant Mouse Hubalek et al. (2004)
FTT_1365 Fructose bis-phosphate aldolase Increased expression No Hubalek et al. (2004)
FTT_1367 Phosphoglycerate kinase Increased expression No Hubalek et al. (2004)
FTT_1369 Transketolase I Increased expression Yes Hubalek et al. (2004)
FTT_1377 3-Oxoacyl-[acyl-carrier-protein] synthase II Charge variant No Hubalek et al. (2004)
FTT_1539c Hypothetical protein FTT__1539c Charge variant Mouse, human Hubalek et al. (2004)
FTT_1651 Conserved hypothetical protein Unique No Pavkova et al. (2006)
FTT_1666 3-Hydroxyisobutyrate dehydrogenase Unique No Pavkova et al. (2006)
FTT_1674 Riboflavin synthase, β subunit Charge variant No Hubalek et al. (2004)
FTT_1769 ClpB protein Increased expression Human Hubalek et al. (2004)
FTT_1794 Heat shock protein Charge variant No Hubalek et al. (2004)
of Francisella in target organs during infection, and thus the over-
all virulence and infectivity of the bacteria (Meibom et al., 2008). 
Finally, three proteins reported in this study were only detected in 
2DE of subspecies tularensis; FTT_0607, 4-hydroxy-3-methylbut-
2-en-1-yl diphosphate synthase, FTT_0435, a carbon–nitrogen 
hydrolase and FTT_1157, a type IV pili lipoprotein. Type IV pilin 
proteins, such as PilA have been shown to play a significant role as 
virulence factors of Francisella (Forslund et al., 2006). The loss of 
the pilA gene also represents one of the major events that has led 
to the marked attenuation of the type B LVS strain (Salomonsson 
et al., 2009). While the pilA gene is present in F. novicida, and in 
pathogenic strains of subspecies holarctica, it does not appear that 
it functions as a component of a functional type IV pilin protein, 
but rather serves as a secretion system (Hager et al., 2006).
A small number of proteins that were expressed at detectable 
levels only in subspecies tularensis, or appear to be expressed in 
greater amounts in this subspecies have also been found to be 
immunoreactive in immune or convalescent sera, as highlighted 
in Table 1. These include the putative virulence factor IglC, which 
is expressed as a unique charge variant in subspecies tularensis, as 
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well as an FKBP-type peptidyl-prolyl cis–trans isomerase family 
protein (FTT_1043). Whilst it has not been conclusively shown 
to be true in Francisella, homologs of the latter protein in other 
intracellular pathogens such as Legionella, Neisseria, Chlamydia, 
and Trypanosomes play a key role in virulence and ensuring the 
uptake of these pathogens by host cells (Hacker et al., 1993; Ludwig 
et al., 1994; Moro et al., 1995; Leuzzi et al., 2005).
Also using gel-based comparative proteomics, the proteome of 
an attenuated, spontaneous mutant of SCHU S4, was compared 
with the parent strain, SCHU S4 (Twine et al., 2005a). The attenu-
ated strain, denoted FSC043, was found to be avirulent in mice and 
outperformed LVS as a live vaccine strain (Twine et al., 2005a). The 
study determined that the strain had undergone a recombination 
event, resulting in the expression of a fusion protein, comprising 
the N-terminal half of the hypothetical protein FTT_0918 and 
the C-terminal half of hypothetical FTT_0919 as a single protein 
(Twine et al., 2005a). A similar defect, resulting in the expression 
of a homologous protein in LVS was also observed (Twine et al., 
2005a), and has been shown to be a key cause of the attenuation 
of LVS in mice (Salomonsson et al., 2009). Early studies did not 
determine the role of the protein, FTT_0918, but show the utility 
of the corresponding deletion mutant as a rationally attenuated 
live vaccine strain in the mouse model of tularemia (Twine et al., 
2005a). Since then, there have been several studies investigating the 
role of these proteins, which have no homology to any other pro-
teins listed in the NCBInr. They have been proposed to be a novel 
family of potentially membrane associated proteins and involved in 
iron uptake and regulation (Lindgren et al., 2009). One study has 
denoted FTT_0918 as fupA, and the hybrid gene in LVS as fupA/B, 
FIGuRE 1 | using 2D-PAGE coupled with mass spectrometric methods for protein identification, Hubalek et al. (2004) identified proteins that 
were unique to specific subspecies, or differentially expressed between them.
with fupAB having a significant role in the siderophore-mediated 
iron uptake mechanism of LVS (Sen et al., 2010). The functional-
ity of the fusion protein in the attenuated SCHU S4 strain has not 
been determined. However, genomics studies alone would have 
been unable to predict the expression of the fusion protein. This 
information has since been exploited in tularemia vaccine devel-
opment for the construction of rationally attenuated live vaccine 
strains (Kadzhaev et al., 2009).
In order to work toward more complete proteome coverage, 
many complementary approaches need to be undertaken, including 
subfractionation of the proteome into, for example, the membrane 
subproteome or glycoproteome.
the Francisella membrane proteome
Membrane proteins, particularly those exposed to the extracellular 
environment, can play important roles in the initial infection stages 
and the overall virulence and survival of the bacteria within a host 
(Haake et al., 2000). Membrane proteins have also been viewed as 
having the potential to act as effective subunit vaccine candidates 
given the frequency with which they are able to promote an immune 
response in a host cell (Sjostedt et al., 1992a; Huntley et al., 2007). 
Thus, efforts have been placed on identifying and characterizing 
Francisella’s membrane proteins (Pavkova et al., 2005, 2006; Melillo 
et al., 2006; Huntley et al., 2007). Early studies aimed at character-
izing outer membrane proteins (OMPs) from F. tularensis studies 
carried out with LVS used bulk membrane extraction techniques, 
including sonication of cells followed by ultracentrifugation and/or 
detergent extraction. These studies did identify OMPs, and assessed 
their potential as subunit vaccines (Sandstrom et al., 1987; Surcel 
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et al., 1989; Ericsson et al., 1994a; Fulop et al., 1996), but also suffered 
low level contamination with periplasmic and/or cytoplasmic com-
ponents (Sandstrom et al., 1987; Surcel et al., 1989; Ericsson et al., 
1994a; Fulop et al., 1996). More recent studies have used sodium 
carbonate enrichment of membrane proteins, in which the addition 
of sodium carbonate preferentially causes membranes to form open 
membrane sheets, whilst cytoplasmic and peripheral membrane 
proteins are released in soluble form (Fujiki et al., 1982). Combined 
with gel-based proteomics approaches, two studies attempted to 
characterize the membrane enriched fraction of LVS (Pavkova et al., 
2005; Twine et al., 2005b). Studies identified numerous candidate 
OMPS, although using the PSORT1b algorithm as a predictor of 
subcellular protein location, fewer than 10 proteins were predicted 
to be OMPs. One group then went further to identify immunogenic 
OMPs, using sera from LVS vaccinated mice. Of the 36 identified 
immunoreactive proteins, PSORTb analyses showed that the major-
ity of the proteins identified in this study were more closely associ-
ated with the cytoplasm and non-membranous regions of the cell, 
thereby reflecting the relatively low specificity of the sodium carbon-
ate enrichment for membrane proteins (Havlasova et al., 2005).
Using density gradient centrifugation, OMPs from LVS and 
SCHU S4 were purified, leading to the identification of 12 OMPs, 
which are listed in Table 2 (Huntley et al., 2007). Interestingly, some 
of the proteins in the enriched native OMP preparation were then 
shown to be immunogenic with F. tularensis infected C3H/HeN 
mice, with antibodies produced toward KatG, PilQ, GroEL, ATP 
synthase, OmpA, FopA, and Tul4-A (Huntley et al., 2007).
Putative outer membrane or cell surface exposed proteins have 
been identified in Francisella as possibly playing a role in the adher-
ence of the bacteria to human lung cells. Using surface biotinylation 
and protein purification by the use of immobilized streptavidin 
beads, one study identified seven putative surface exposed proteins; 
Chaperone protein DnaK (FTT_1269), chaperone protein GroEL 
(FTT_1696), hypothetical membrane protein (FTT_0119), Outer 
Table 2 | Francisella tularensis LVS outer membrane proteins, isolated 
using density gradient centrifugation.
Accession 
number
Protein name Reference
FTT_0842 Peptidoglycan-associated lipoprotein Huntley et al. (2007)
FTT_1095c Hypothetical protein Huntley et al. (2007)
FTT_1724c Outer membrane protein tolC  
precursor
Huntley et al. (2007)
FTT_1156c Type IV pilin multimeric outer 
membrane protein
Huntley et al. (2007)
FTT_1258 Outer membrane efflux protein Huntley et al. (2007)
FTT_1573c Outer membrane protein Huntley et al. (2007)
FTT_0583 Outer membrane associated protein Huntley et al. (2007)
FTT_1043 FKBP-type peptidyl-prolyl cis–trans 
isomerase family protein
Huntley et al. (2007)
FTT_0918 Hypothetical protein Huntley et al. (2007)
FTT_0919 Hypothetical protein Huntley et al. (2007)
FTL_0439 YapH-LVS Huntley et al. (2007)
FTT_0729 ABC transporter, membrane protein Janovska et al. (2007a)
membrane associated protein FopA (FTT_0583),  intracellular 
growth locus, subunit A (FTT_1714), conserved hypothetical 
lipoprotein (FTT_1347), and hypothetical protein (FTT_1441), 
also identified as bacterioferritin in LVS (Melillo et al., 2006). Of 
particular interest to this study was hypothetical membrane pro-
tein FTT_0119, also annotated as FsaP in LVS. When expressed in 
a non-adhering Escherichia coli strain, this protein enabled E. coli 
to adhere to A549 human lung epithelial cells. Furthermore, it has 
been shown that FsaP is present on the cell surface of F. tularen-
sis subsp. holarctica, which readily adheres to this same cell line. 
However, it is absent from the cell surface of F. novicida, which 
is unable to effectively adhere to A549 cells. Combined with the 
observed increased expression this protein in vivo (Twine et al., 
2006a), and the production of antibodies in response to FsaP during 
tularemia infection, FTT_0119 could become a point of interest in 
exploring the pathogenesis of F. tularensis (Melillo et al., 2006).
the Francisella glycoproteome
The long prevailing dogma that bacteria cannot modify proteins 
with carbohydrate moieties is being met with an increasing amount 
of evidence to the contrary. Discovery and characterization of bac-
terial glycoproteins presents many challenges, including the often 
unknown nature of the modifying carbohydrate moiety. Many 
 studies focus upon characterization of a single purified protein whilst 
others are attempting to conduct more encompassing studies of the 
entire bacterial glycoproteome. Preliminary work strongly suggests 
that F. tularensis strains modify multiple proteins with unknown 
glycan moieties, although the covalent attachment of carbohydrate 
moieties to specific proteins has yet to be demonstrated.
Often the first indication that a protein is modified by glycan 
is aberrant migration on 1D- or 2D-PAGE. A type IV pilin pro-
tein, pilA (FTT_0890) was shown using 2DE to migrate to 18 kDa; 
a higher molecular weight than that predicted by the pilA gene 
sequence (14 kDa), suggesting post-translational modification 
(Forslund et al., 2006). Additionally, pilA from Francisella was 
cloned into a strain of P. aeruginosa that is known not to glyco-
sylate type IV pilin proteins. Francisella PilA was expressed, but 
further analysis showed that the approximate molecular weight 
was 14 kDa; close to the mass predicted from the translated pilA 
gene sequence. Evidence of homologous pilin protein glycosylation 
in other intracellular, bacterial pathogens such as Neisseria and 
some strains of P. aeruginosa (Stimson et al., 1995; Banerjee and 
Ghosh, 2003) also supports the hypothesis that this protein may 
be glycosylated in Francisella.
Another study, exploited glycoproteomics approaches developed 
and optimized for the detection of eukaryotic glycans. Balonova 
et al. (2010) reported the identification of 31 putative Francisella 
glycoproteins. Detection and enrichment of putative glycoproteins 
was carried out using an in-gel glycostaining kit, and a lectin based 
glycan differentiation. A total of 11 proteins were observed to be 
reactive with the gel-based glycostain, which relies upon carbo-
hydrate diol groups, which are oxidized to aldehydes, and sub-
sequently form a stable hydrozone in reaction to a fluorescently 
labeled hydrazide. Lectin affinity resulted in the enrichment and 
identification of 20 putative glycoproteins, although none have to 
date been conclusively reported as glycoproteins and the role of 
protein glycosylation in Francisella pathogenesis is unknown.
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subspecies. In all subspecies the FPI is present in two identical 
copies and has been shown to code for several putative virulence 
factors. Within the FPI are 16 genes that have been found to be 
highly conserved across each of the four subspecies, leaving an 
additional 2–3 genes that display greater variability. These variable 
genes; pmcA and pdpD in F. novicida, may be absent from subspe-
cies such as holarctica or present but interrupted or abbreviated, 
as in subspecies tularensis. However, the levels at which the FPI 
gene products are produced can vary between subspecies. PigA 
(FTT_1701/1346), for example, is present in a two- to sixfold 
greater abundance in SCHU S4, a subspecies tularensis strain, 
than in other subspecies (Pavkova et al., 2006). It has also been 
suggested however, that virulence factors coded for by the FPI 
can be regulated by genes not contained in the FPI itself. MglA, 
for example, has been found to be a major regulator of several 
virulence factors encoded both within and outside of the FPI 
(Lauriano et al., 2004).
The iglABCD operon is one of the most highly studied regions 
within the FPI with IglC being among the first of the FPI proteins 
to be elucidated. In a study by Golovliov et al. (1997), protein induc-
tion of F. tularensis during growth in macrophages was explored. 
Using protein radiolabeling coupled with 1D- and 2D-PAGE, a 
novel 23 kDa protein, later identified as IglC, was determined to 
be significantly induced during growth in macrophages and was 
sequenced using Edman degradation (Golovliov et al., 1997). Here, 
the gene products represent putative virulence factors, and their 
absence renders Francisella either avirulent or extremely attenuated 
(Golovliov et al., 2003b; Nix et al., 2006). Without IglA, F. tularensis 
has been shown to be entirely avirulent in a chicken embryo model, 
due to its inability to grow within macrophages (Nix et al., 2006). 
This growth has been found to be an intrinsic part of the patho-
genicity of F. tularensis (Nix et al., 2006). Additional research has 
speculated that IglA associates with IglB in the cytoplasm, as they 
have been found to co-precipitate and insertions into the iglB gene 
results in the loss of detection of IglA as well (de Bruin et al., 2007). 
Such observations have led to the suggestion that the removal of 
either IglA or IglB may allow for the intracellular degradation of 
the other (de Bruin et al., 2007).
Modifications to IglC and its expression also result in a mutant 
that is severely hindered in its ability to grow in macrophages 
(Golovliov et al., 2003a). IglD too, is essential for intracellular rep-
lication in both mouse and monocyte derived macrophage studies 
(Santic et al., 2005).Where growth is possible, deletions of the iglC 
gene in LVS, for example, often resulted in a mutant unable to 
escape from phagosomes and it was therefore unable to effectively 
disseminate from the original site of infection (Telepnev et al., 
2005). Regardless of the subspecies in which IglC was removed, 
mutants exhibited avirulence in the models they were tested in 
Golovliov et al. (2003a). It does not appear, however, that iglC plays 
a significant role in regulating protein expression during oxidative 
stress (Lenco et al., 2005). A ∆iglC LVS mutant showed very similar 
changes in protein expression to that of LVS when in the presence 
of hydrogen peroxide; namely the upregulation of approximately 
10 proteins. The only significant difference between protein expres-
sion of LVS and ∆iglC in the presence of hydrogen peroxide was 
the increased expression of AhpC/TSA family protein in the ∆iglC 
mutant (Lenco et al., 2005).
the Francisella in vivo proteome
The capacity of F. tularensis to cause disease appears to be a reflec-
tion of its ability to multiply intracellularly and damage various 
host organs rather than its ability to produce any specific toxins. 
This requires F. tularensis to subvert or otherwise avoid a vari-
ety of host defenses that possess the potential to kill it. In par-
ticular, F. tularensis multiplies extensively in macrophages in vitro 
and in vivo (Golovliov et al., 1997; Conlan et al., 2002). Studies 
have been carried out which attempt to mimic one or more of 
the stress responses to which F. tularensis may be exposed during 
proliferation within the host. Changes in the bacterial proteome 
in response to exposure to hydrogen peroxide, hoping to mimic 
the an oxidative stress response showed elevated levels of chaper-
onins such as GroEL, DnaK and stress response proteins such as 
ClpB, SodB (Ericsson et al., 1994b; Lenco et al., 2005; Twine et al., 
2006a). Virulence factors, such as the pathogenicity island protein, 
IglC were also identified in some of these studies. Other studies 
have grown strains under conditions of iron restriction (Lenco 
et al., 2007), and manipulated growth temperatures (Lenco et al., 
2009) hoping to mimic conditions to which the pathogen will be 
exposed within the host environment. Such in vitro studies offer a 
facile means of dissecting the response of the bacterial proteome to 
individual stress conditions, and some groups are working toward 
developing in vitro growth conditions that more closely mimic 
the host environment (Hazlett et al., 2008). Others have studied 
bacteria during intracellular growth in a macrophage model of 
tularemia and identified induced proteins (Golovliov et al., 1997; 
Kovarova et al., 2002). However, these studies still cannot neces-
sarily accurately represent the myriad of stimuli to which the bac-
terium is exposed in the host environment. Attempting to study 
the proteome of bacteria growing within host tissues is extremely 
challenging, with limited reports of proteomes of pathogens iso-
lated from host tissues (Becker et al., 2006; Twine et al., 2006a). An 
immunomagnetic separation approach was used to rapidly isolate 
bacteria from spleen tissues of mice infected with type A F. tularensis 
strain FSC033. In total, 78 proteins were shown to be differentially 
expressed when compared to the proteomes of the strain grown in 
liquid media. Of the proteins increased in expression some, such 
as IglC and chaperonins are also observed at higher levels in bac-
teria exposed to oxidative stress conditions. There were, however, 
a small number of proteins that were only observed at detectable 
levels in bacteria isolated from spleen tissues, including a cobala-
min synthesis protein, universal stress protein and glycine cleavage 
system protein. These proteins are likely to be factors required for 
intracellular adaptation of the bacterium, rather than virulence 
factors. This study was the first attempt to determine the reper-
toire of proteins expressed by F. tularensis during proliferation in 
the hostile host environment, yet only provides a snapshot of the 
bacterial proteome, toward the latter stages of tularemia. Of greater 
interest, but also much more challenging, would be the isolation 
and proteome characterization of bacteria at the site of infection, 
during dissemination to host organs.
Francisella vIrulence factors
Also included in comparative proteomics studies, has been the 
analysis of the Francisella pathogenicity island (FPI); a highly 
conserved 16–19 gene cluster found in each of the four Francisella 
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The FPI itself contains several putative virulence factors, many 
of which may be common to all four Francisella subspecies, but 
it is not the only region of the genome that contains potential 
virulence factors.
The list of proteins with a potential role in pathogenesis is 
extensive. Despite the apparent diversity amongst these proteins 
though, there are several main classes into which these factors 
can be divided, including the FPI-encoded virulence factors that 
have already been discussed. Often, possible virulence factors are 
surface associated and may be part of a capsule, the lipopolysac-
charide (LPS) or having to do with a type IV pili system. Proteins, 
such as the pilin subunit have been shown in Francisella strains, 
to have a role in host-cell recognition, virulence (Forslund et al., 
2006, 2010), protein secretion (Hager et al., 2006), and adherence 
to host cells (Chakraborty et al., 2008). FTT_0918, a hypothetical 
protein present in both subsp. tularensis and in the LVS strain of 
holarctica, is thought to be membrane associated (Huntley et al., 
2007). Transcriptional regulators such as MglA have also been 
shown to have an essential role in the virulence and pathogenesis 
of Francisella (Lauriano et al., 2004). Francisella also possesses 
large numbers of hypothetical proteins and lipoproteins, such 
as conserved hypothetical protein FTT_1103, that have been 
implicated as virulence factors (Qin et al., 2009). The virulence 
factors described here were elucidated through various proteom-
ics studies and only begin to unravel Francisella’s mechanisms 
of virulence.
approaches to study reactIvIty of Francisella 
proteIns wIth antIbodIes
Scientists have been studying the antibody response to vaccina-
tion or infection with Francisella for many years. This has been 
accomplished by methods such as agglutination (Engelfried and 
Spear, 1966), ELISA (Carlsson et al., 1979), and 1D-Western blot-
ting (Bevanger et al., 1988). Early work was often unable to defin-
itively identify the immunoreactive proteins, but more recently 
2D-Western blotting combined with protein identification by mass 
spectrometry has been exploited. The term “immunoproteomics” 
has been coined to describe such studies. A newer approach, pro-
teome microarray technology, prints recombinant proteins on glass 
slides to allow high throughput screening of immune sera. Each 
approach is outlined briefly here, including a discussion of the 
strengths and weaknesses of each.
western blottIng
The 2D-Western blotting approach, combines 2D separation of 
the antigen with Western blotting. The antigen used in these 
studies is usually a bacterial cell lysate, or subproteome fraction 
(e.g., membrane) of in vitro grown bacteria. 2D-PAGE resolves 
the majority of bacterial proteins to a single protein spot, and 
retains the native protein processing and post-translational 
modifications. Proteins are transferred to nitrocellulose or PVDF 
membrane, and probed with primary sera and conjugated sec-
ondary antibody, as per traditional Western blotting (protocol 
is outlined in Gallagher et al., 2008). Proteins may be stained 
after transfer to a membrane, and the captured image used to 
align regions of immunoreactivity with areas of protein staining. 
Excising the identified immunoreactive proteins from a second 
protein stained 2D-PAGE, and subsequent digestion with trypsin 
allows identification of proteins using mass spectrometry based 
techniques (e.g., MS/MS).
2D-Western blotting is one of the most accessible immuno-
proteomics approaches, that can be carried out in any labora-
tory equipped with gel-based electrophoresis and electroblotting 
equipment. It has, therefore, been adopted in many immuno-
proteomics studies. Despite its wide use, the approach has some 
disadvantages, which are largely related to limitations of gel-based 
2D protein separations, including difficulties in resolving very 
large, small, hydrophobic or basic proteins. The analysis is also 
limited to those proteins expressed by bacteria under in vitro 
growth conditions, which may not be representative of the pro-
teome expressed by the pathogen when proliferating in the host 
environment. 2D-Western blotting using bacteria isolated from 
host tissues has been carried out in tularemia proteomics work 
(Twine et al., 2006a), however the limited amount of antigen 
isolated makes this challenging to do with more than a few serum 
samples. In addition, the abundance of expressed proteins, what-
ever the growth conditions, can vary from a few copy numbers 
per cell to millions, therefore the observed intensity of immuno-
reactivity may not be representative of the immunogenicity of 
the protein, but its abundance. The relatively low throughput of 
2D-Western blotting and mass spectrometry can be a bottleneck 
in immunoproteomics studies. Large format 2D gels offer supe-
rior proteome resolution, but the complete 2D-Western blotting 
experiment typically takes 4–5 days to perform. Experiments can 
be multiplexed, depending upon the resources of the lab, but this is 
still a relatively slow and laborious process. Despite the limitations 
of this approach, it remains by far the most accessible approach 
for most laboratories.
ImmunoproteomIcs usIng a proteIn mIcroarray
The bacterial proteome microarray has been described in a number 
of reports, including two studies conducted with Francisella immune 
sera (Eyles et al., 2007; Sundaresh et al., 2007). The construction of 
the bacterial proteome microarray consists of three steps; a single-
round PCR to amplify each open reading frame (ORF), followed 
by in vivo recombination cloning and in vitro protein expression 
and microarray printing (Eyles et al., 2007). Specifically, the PCR 
primers are designed with a gene specific portion, and an adaptor 
sequence. The adaptor sequences flank the amplified gene and 
are homologous to portions of the cloning vector (pXT7). The 
PCR products are cloned into the expression vector by in vivo 
homologous recombination using competent E. coli DH5α cells. 
The resulting clone also harbors an ATG start codon, polyhistidine 
and hemagglutinin tags. Proteins are expressed using commercially 
available in vitro transcription/translation kits and the resulting 
proteins printed directly onto nitrocellulose coated glass slides. 
This method allows the entire proteome of F. tularensis SCHU 
S4, comprising 1741 ORFs onto a single slide (Eyles et al., 2007). 
The chips are then treated in a manner analogous to traditional 
Western blotting; the chips are incubated with blocking buffer, 
then primary immune sera, washed, incubated with a conjugated 
secondary antibody, with detection of the fluorescent conjugate 
performed by a microarray scanner. It is reported that upwards 
of 800 sera could be process in a single experiment.
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The proteome microarray has many advantages compared with 
2D-Western blotting approach. Firstly, the antigens are presum-
ably present at equal concentrations in contrast with gel-based 
approaches, where the concentration of each protein is dependent 
upon expression levels during in vitro bacterial growth. In addition, 
if desired the entire theoretical proteome of the organism can be 
interrogated. Proteome microarrays also offer multiplexing, high 
throughput, and reduced serum volume requirements (2 μl ver-
sus ∼50–100 μl for large 2D-Western blot). However, the proteins 
printed on the chip likely do not harbor native post-translational 
modifications, and may not be post-translationally processed in the 
same manner as native Francisella proteins, a drawback common to 
most recombinant protein expression systems. Other disadvantages 
include the cost and feasibility; many labs which are equipped to 
perform standard proteomic experiments are not able to fabricate 
proteome microarrays, and analysis, at present, is limited to spe-
cialist laboratories.
ImmunoproteomIcs of Francisella tularensis
In the following sections, we will review the immunoproteomics 
studies reported in the literature to date, including characteris-
tics of the identified immunoreactive proteins and a brief com-
parison of the proteins identified using gel-based and proteome 
microarray studies.
ImmunoproteomIcs In the murIne model of tularemIa
The majority of our recent knowledge on the pathogenesis of 
F. tularensis infection has been derived from studies of mice 
infected with either the attenuated live vaccine strain (LVS) or 
virulent strains of F. tularensis by the intradermal (i.d.) or respi-
ratory route (Golovliov et al., 1996; Conlan et al., 2003; Elkins et al., 
2003; Wu et al., 2005) and more recently oral route (Kuolee et al., 
2007). Studies have included mice of various genetic backgrounds, 
including immunodeficient mice (Chen et al., 2004), mouse strains 
deficient in Toll-like receptor 4 (TLR4) signaling (Macela et al., 
1996). In the following sections, we review the current knowledge 
of Francisella immunoproteomics, carried out using the murine 
model of tularemia.
successful versus unsuccessful vaccination of mice
TLR4, the signal transducing element of the LPS receptor complex, 
is thought to play an important role in innate immunity against 
Gram-negative bacteria (Underhill, 2004). TLR4-defective (TLR4d) 
mice (C3H/HeJ) are reported to be more susceptible to subcuta-
neous challenge with LVS than wild type (TLR4+/+) mice (C3H/
HeN). The LD50 of the pathogen was 100-fold lower for C3H/HeJ 
mice compared with that for C3H/HeN mice (Macela et al., 1996). 
A follow-up study used gel-based immunoproteomics to compare 
the repertoire of immunoreactive proteins generated by C3H/HeN 
and C3H/HeJ mice in response to infection with LVS (Havlasova 
et al., 2005). The immunoreactive proteins identified in this study 
are summarized in Table 3. Of particular interest, this study moni-
tored the immunoblotting patterns of sera drawn from mice over 
a 28-day period post-LVS infection, and reported that sera from 
infected C3H/HeJ had higher antibody titers, compared with C3H/
HeN mice, up to 21 days post-infection. Despite this observation, 
the antibody patterns observed for each mouse strain were directed 
toward an almost identical subset of antigens (Havlasova et al., 
2005). This study suggests, that in these mouse strains, protective 
immunity may not be dependent upon antibodies.
Another study exploited the differing susceptibility of four 
mouse strains to protective vaccination with an LVS strain derived 
from ATCC LVS, in order determine whether a subset of immu-
noreactive proteins would be predictive of protective vaccination. 
LVS inoculated intradermally elicits a similar sub-lethal infection 
in the skin, liver, and spleen of both BALB/c and C57BL/6 mice that 
persists for approximately 2 weeks (Chen et al., 2003). However, 
whereas this infection renders BALB/c and CH3/HeN mice immune 
to a subsequent systemic challenge with a virulent type A strain of 
F. tularensis, it fails to protect C57BL/6 mouse strains from a 100-
fold smaller challenge (Chen et al., 2003). The repertoire of proteins 
reactive only with sera from mouse strains that were successfully 
vaccinated with LVS (BALB/c, CH3/HeN) were compared with 
immunoreactive proteins from strains that cannot be successfully 
vaccinated with LVS (C57BL/6, DBA). The difference in protec-
tive immunity of these mouse strains was hoped to reveal specific 
antigenic markers of protective immunity. The mouse strains suc-
cessfully vaccinated with LVS, harbored antibodies toward a small 
set of proteins, that were not reactive with immune sera from vac-
cinated but unprotected mice, but no overall conclusion regarding 
patterns of protective immunoreactivity were drawn (Twine et al., 
2006b; Table 3).
A more recent study used an almost identical approach of 
exploiting the varying ability of LVS vaccination to protect BALB/c 
and C57/BL6 mouse strains against type A challenge with LVS. 
This study differed in the LVS preparation, using a new lot of LVS, 
denoted lot 17. This LVS vaccine lot was produced in compliance 
with Current Good Manufacturing Practice (CGMP) guidelines 
and this new vaccine formulation was evaluated in a recent Phase 
1 clinical study in humans (El Sahly et al., 2009). When compared 
to the previous work (Twine et al., 2006b), there are distinct dif-
ferences in the observed immunoreactive proteins, which could 
potentially be attributed to the vaccinating strain of LVS. However, 
this study, identified nine proteins that were reactive with sera from 
lot 17 LVS vaccinated BALB/c mice, that were not observed to be 
reactive with sera from unsuccessfully vaccinated C57/BL6 mice 
(Twine et al., 2010). The proteins are listed in Table 3 and in addi-
tion, Figure 2 shows the similarities and differences in the profile 
of immunoreactive proteins identified in this study. The majority 
of the nine proteins have been observed to be reactive with sera 
from other murine or human tularemia studies and could have 
potential as markers of successful vaccination.
vaccination of mice with killed lvs
During the 1920s and 1930s there was a significant effort to develop 
killed F. tularensis vaccines, due to the reduced intrinsic safety 
and liability concerns, compared with live vaccines. Studies with 
heat or formalin killed Francisella strains showed that vaccines 
made using these methods are generally ineffective (Foshay et al., 
1942; Kadull et al., 1950). However, recent work showed that LVS 
killed by irradiation, and administered to mice in combination 
with either alum, and immunostimulating complexes (ISCOMs) 
or CpG afforded some protection against challenge with virulent 
type B or A strains (Eyles et al., 2007). In addition, the authors used 
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Table 3 | Proteins which are recognized by sera from convalescent humans or from LVS vaccinated mice.
Locus tag Protein name Gene Reactivity sera1 Screening method2 PSORT3 Reference
FTT_0018 Secretion protein Human Proteome microarray Cytoplasmic 
membrane
Sundaresh et al. (2007)
FTT_0037 NADH dehydrogenase I G subunit Mouse 2D-Western blot Unknown Twine et al. (2010)
FTT_0049 N utilization substance protein A nusA Mouse 2D-Western blot Cytoplasmic Twine et al. (2006a)
FTT_0060 ATP synthase B chain atpF Mouse Proteome microarray Cytoplasmic Eyles et al. (2007)
FTT_0062 ATP synthase alpha chain atpA Mouse 2D-Western blot Unknown Twine et al. (2006b, 2010)
FTT_0064 ATP synthase beta chain Mouse 2D-Western blot Cytoplasmic Huntley et al. (2007), Twine 
et al. (2010)
FTT_0071 Citrate synthase gltA Mouse 2D-Western blot Cytoplasmic Havlasova et al. (2005)
FTT_0074 Succinate dehydrogenase catalytic  
and NAD flavoprotein subunit
shdA Human, presumed 
type B; mouse
2D-Western blot Unknown Twine et al. (2006b), Janovska 
et al. (2007a)
FTT_0075 Succinate dehydrogenase iron- 
sulfur subunit
sdhB Mouse 2D-Western blot Cytoplasmic Twine et al. (2006b)
FTT_0077 Dihydrolipoamide succinyltransferase 
component of 2-oxoglutarate 
dehydrogenase complex
sucB Human, type A; 
human, presumed 
type B; mouse
Proteome 
microarray/2D- 
Western blot
Cytoplasmic Twine et al. (2006b), Eyles et al. 
(2007), Janovska et al. 
(2007a,b), Sundaresh et al. 
(2007), Twine et al. (2010)
FTT_0083 Hypothetical membrane protein Human, presumed 
type B
Proteome microarray Unknown Sundaresh et al. (2007)
FTT_0086 Hypothetical protein – Mouse 2D-Western blot Unknown Twine et al. (2006b)
FTT_0087 Aconitate hydratase Human, type A; 
human, presumed 
type B; mouse
2D-Western blot Cytoplasmic Janovska et al. (2007a,b), Twine 
et al. (2010)
FTT_0101 Conserved membrane hypothetical 
protein
– Human, presumed 
type B; mouse
Proteome microarray Cytoplasmic 
membrane
Eyles et al. (2007), Sundaresh 
et al. (2007)
FTT_0106 Efflux protein, RND family, MFP 
subunit
– Human, presumed 
type B; mouse
Proteome microarray Cytoplasmic 
membrane
Eyles et al. (2007), Sundaresh 
et al. (2007)
FTT_0119 Hypothetical membrane protein – Human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Unknown Eyles et al. (2007), Sundaresh 
et al. (2007), Twine et al. 
(2006a)
FTT_0123 Pseudogene Human, presumed 
type B
Proteome microarray Cyt mem Sundaresh et al. (2007)
FTT_0137 Elongation factor Tu tufA Human, presumed 
type B; mouse 
2D-Western blot Cytoplasmic Havlasova et al. (2002, 2005), 
Twine et al. (2006a,b, 2010), 
Janovska et al. (2007a)
FTT_0141 50S ribosomal protein L1 rplA Mouse 2D-Western Blot Unknown Twine et al. (2006b)
FTT_0143 50S ribosomal protein L7/L12 rplL Human, presumed 
type B; mouse
2D-Western blot Unknown Havlasova et al. (2002, 2005), 
Twine et al. (2006a,b), Janovska 
et al. (2007a)
FTT_0183c 30S ribosomal protein S1 rpsA Mouse 2D-Western blot Cytoplasmic Twine et al. (2006b, 2010)
FTT_0188 Cell division protein ftsZ Human, presumed 
type B; mouse
2D-Western blot Cytoplasmic Twine et al. (2006b, 2010), 
Janovska et al. (2007a)
FTT_0189 UDP-3-O-[3-hydroxymyristoyl] Mouse 2D-Western Blot Unknown Twine et al. (2010)
FTT_0194 Conserved hypothetical membrane 
protein 
Human, presumed 
type B
Proteome microarray Cyt mem Sundaresh et al. (2007)
FTT_0196c Glutamine synthetase glnA Mouse Proteome microarray Cytoplasmic Eyles et al. (2007)
FTT_0208c ABC transporter, ATP-binding protein Mouse 2D-Western blot Unknown Twine et al. (2006b)
FTT_0209c Periplasmic solute binding family 
protein
– Mouse 2D-Western blot Unknown Twine et al. (2006a,b, 2010)
FTT_0233 Inner-membrane protein yidC Mouse Proteome microarray Cytoplasmic 
membrane
Eyles et al. (2007)
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FTT_0630 Host factor I for bacteriophage  
Q beta replication
hfq Mouse 2D-Western blot/
proteome microarray
Cytoplasmic Havlasova et al. (2005), Eyles 
et al. (2007)
FTT_0682 Hypothetical protein – Human, presumed 
type B; mouse
Proteome microarray Periplasmic Eyles et al. (2007), Sundaresh 
et al. (2007)
FTT_0708 Major facilitator superfamily (MFS) 
transport protein
Human, presumed 
type B
Proteome microarray Cytoplasmic 
membrane
Sundaresh et al. (2007)
FTT_0715 Chitinase family protein – inner 
membrane
Mouse 2D-Western blot Unknown Havlasova et al. (2005), Twine 
et al. (2006b, 2010)
FTT_0721c Peroxidase/catalase katG Human type A; 
human, presumed 
type B; mouse
2D-Western blot Periplasmic 
space/outer 
membrane
Havlasova et al. (2005), Twine 
et al. (2006a,b, 2010), Huntley 
et al. (2007), Janovska et al. 
(2007a,b
FTT_0724 Part of pseudogene dacB1 – Mouse Proteome microarray – Eyles et al. (2007)
FTT_0726c Glycerophosphoryl diester 
phosphodiesterase family protein
Human, presumed 
type B
2D-Western blot Unknown Janovska et al. (2007a)
FTT_0756 Cation-efflux family protein – Mouse Proteome microarray Cytoplasmic 
membrane
Eyles et al. (2007)
FTT_0817 Threonyl-tRNA synthetase thrS Mouse 2D-Western blot Cytoplasmic Twine et al. (2006b)
FTT_0831c OmpA family protein – Human, presumed 
type B; mouse
Proteome 
microarray/2D- 
Western blot
Unknown Eyles et al. (2007), Huntley 
et al. (2007), Janovska et al. 
(2007a), Twine et al. (2010)
FTT_0849 Bile acid symporter family protein Human, presumed 
type B
Proteome microarray Cytoplasmic 
mem
Sundaresh et al. (2007)
FTT_0863 LemA-like protein – Human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Cytoplasmic Twine et al. (2006b, 2010), 
Eyles et al. (2007), Janovska 
et al. (2007a), Sundaresh et al. 
(2007)
FTT_0869 Hypothetical protein – Human, presumed 
type B; mouse
Proteome microarray Unknown Eyles et al. (2007), Sundaresh 
et al. (2007)
FTT_0901 Conserved hypothetical lipoprotein 
(17 kDa major membrane protein 
precursor)
lpnA Human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Unknown Havlasova et al. (2002), Eyles 
et al. (2007), Huntley et al. 
(2007), Janovska et al. (2007a)
FTT_0918 Hypothetical protein – Human type A; 
mouse
2D-Western blot Outer 
membrane
Twine et al. (2006a, Janovska 
et al. (2007b)
FTT_0949 Pseudogene Human, presumed 
type B
Proteome microarray Unknown Sundaresh et al. (2007)
FTT_0956c Hypothetical membrane protein – Human, presumed 
type B; mouse
Proteome microarray Unknown Eyles et al. (2007), Sundaresh 
et al. (2007)
FTT_0975 Hypothetical protein – Human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Unknown Havlasova et al. (2005), Eyles 
et al. (2007), Sundaresh et al. 
(2007)
FTT_0989 Hypothetical protein – Human, presumed 
type B
Proteome microarray Unknown Sundaresh et al. (2007)
FTT_0991 Hypothetical lipoprotein Human, presumed 
type B
Proteome microarray Unknown Sundaresh et al. (2007)
FTT_1043 FKBP-type peptidyl-prolyl cis–trans 
isomerase family protein
– Mouse 2D-Western blot Outer 
Membrane
Twine et al. (2006b)
FTT_1060c 50S ribosomal protein L9 rplI Human, presumed 
type B; mouse
2D-Western blot Cytoplasmic Havlasova et al. (2002, 2005), 
Twine et al. (2006b, 2010)
FTT_1097 Hypothetical protein – Mouse Proteome microarray Unknown Eyles et al. (2007)
(Continued)
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FTT_0280 Major facilitator superfamily (MFS) 
transport protein
Human, presumed 
type B
Proteome microarray Cyt mem Sundaresh et al. (2007)
FTT_0296 Pyrrolidone-carboxylate peptidase pcp Mouse 2D-Western blot/
proteome microarray
Unknown Havlasova et al. (2005), Eyles 
et al. (2007)
FTT_0313 30S ribosomal protein S2 rpsB Mouse 2D-Western blot Unknown Twine et al. (2006b)
FTT_0314 Protein chain elongation factor EF-Ts tsf Mouse 2D-Western blot/
proteome microarray
Cytoplasmic Havlasova et al. (2005), Twine 
et al. (2006a,b), Eyles et al. 
(2007)
FTT_0323 Elongation factor G fusA Mouse 2D-Western blot Cytoplasmic Twine et al. (2006b, 2010)
FTT_0342 30S ribosomal protein S5 rpsE Mouse 2D-Western blot Unknown Twine et al. (2006b)
FTT_0350 DNA-directed RNA polymerase rpoA1 Mouse 2D-Western blot Cytoplasmic Twine et al. (2006a, 2010)
FTT_0356 Heat shock protein htpG Human, presumed 
type B; mouse
2D-Western blot Cytoplasmic Havlasova et al. (2005), Twine 
et al. (2006b), Janovska et al. 
(2007a)
FTT_0373c Nucleoside diphosphate kinase ndk Mouse 2D-Western blot Cytoplasmic Havlasova et al. (2005), Twine 
et al. (2006b)
FTT_0385 Hypothetical protein – Mouse Proteome microarray Unknown Eyles et al. (2007)
FTT_0394 Hypothetical protein Human, presumed 
type B
2D-Western blot Unknown Havlasova et al. (2002)
FTT_0407 Glycine cleavage complex protein T gcvT Human, presumed 
type B; mouse
2D-Western blot Cytoplasmic Havlasova et al. (2002, 2005)
FTT_0448c Glutaminyl-tRNA synthetase glnS Mouse 2D-Western blot Cytoplasmic Twine et al. (2006b)
FTT_0471 3-Dehydroquinate dehydratase aroD Human, presumed 
type B
2D-Western blot Cytoplasmic Havlasova et al. (2002)
FTT_0472 Acetyl-CoA carboxylase, biotin  
carboxyl carrier protein subunit
accB Human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Unknown Havlasova et al. (2002), Twine 
et al. (2006b, 2010), Eyles et al. 
(2007), Janovska et al. (2007a), 
Sundaresh et al. (2007)
FTT_0473 Acetyl-CoA carboxylase, biotin 
carboxylase subunit
accC Mouse 2D-Western blot Cytoplasmic Havlasova et al. (2005)
FTT_0479 PerM family Human, presumed 
type B
Proteome microarray Cytoplasmic 
membrane
Sundaresh et al. (2007)
FTT_0503 Succinyl-CoA synthetase sucD Mouse 2D-Western blot Cytoplasmic Havlasova et al. (2005), Twine 
et al. (2006b)
FTT_0504c Succinyl-CoA synthetase subunit beta Human type A 2D-Western blot Cytoplasmic Janovska et al. (2007b)
FTT_0510 DNA gyrase subunit B Mouse 2D-Western blot Cytoplasmic Twine et al. (2010)
FTT_0511 Pyridoxine/pyridoxal 5-phosphate 
biosynthesis protein
– Mouse 2D-Western blot Cytoplasmic Twine et al. (2006a, 2010)
FTT_0535c Malate dehydrogenase mdh Mouse 2D-Western blot Cytoplasmic Havlasova et al. (2005)
FTT_0557 lemA-like protein Human, presumed 
type B
2D-Western blot Unknown Janovska et al. (2007a)
FTT_0580 Hypothetical protein Mouse 2D-Western blot Cytoplasmic Twine et al. (2010)
FTT_0583 Outer membrane associated protein fopA Human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Outer 
membrane
Havlasova et al. (2005), Twine 
et al. (2006a,b, 2010), Eyles 
et al. (2007), Huntley et al. 
(2007), Janovska et al. (2007a)
FTT_0614 Apolipoprotein N-acyltransferase Human, presumed 
type B
Proteome microarray Cytoplasmic 
mem
Sundaresh et al. (2007)
FTT_0627 DNA binding protein hupB Human, presumed 
type B
2D-Western blot Unknown Havlasova et al. (2002), 
Janovska et al. (2007a)
(Continued)
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FTT_0630 Host factor I for bacteriophage  
Q beta replication
hfq Mouse 2D-Western blot/
proteome microarray
Cytoplasmic Havlasova et al. (2005), Eyles 
et al. (2007)
FTT_0682 Hypothetical protein – Human, presumed 
type B; mouse
Proteome microarray Periplasmic Eyles et al. (2007), Sundaresh 
et al. (2007)
FTT_0708 Major facilitator superfamily (MFS) 
transport protein
Human, presumed 
type B
Proteome microarray Cytoplasmic 
membrane
Sundaresh et al. (2007)
FTT_0715 Chitinase family protein – inner 
membrane
Mouse 2D-Western blot Unknown Havlasova et al. (2005), Twine 
et al. (2006b, 2010)
FTT_0721c Peroxidase/catalase katG Human type A; 
human, presumed 
type B; mouse
2D-Western blot Periplasmic 
space/outer 
membrane
Havlasova et al. (2005), Twine 
et al. (2006a,b, 2010), Huntley 
et al. (2007), Janovska et al. 
(2007a,b
FTT_0724 Part of pseudogene dacB1 – Mouse Proteome microarray – Eyles et al. (2007)
FTT_0726c Glycerophosphoryl diester 
phosphodiesterase family protein
Human, presumed 
type B
2D-Western blot Unknown Janovska et al. (2007a)
FTT_0756 Cation-efflux family protein – Mouse Proteome microarray Cytoplasmic 
membrane
Eyles et al. (2007)
FTT_0817 Threonyl-tRNA synthetase thrS Mouse 2D-Western blot Cytoplasmic Twine et al. (2006b)
FTT_0831c OmpA family protein – Human, presumed 
type B; mouse
Proteome 
microarray/2D- 
Western blot
Unknown Eyles et al. (2007), Huntley 
et al. (2007), Janovska et al. 
(2007a), Twine et al. (2010)
FTT_0849 Bile acid symporter family protein Human, presumed 
type B
Proteome microarray Cytoplasmic 
mem
Sundaresh et al. (2007)
FTT_0863 LemA-like protein – Human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Cytoplasmic Twine et al. (2006b, 2010), 
Eyles et al. (2007), Janovska 
et al. (2007a), Sundaresh et al. 
(2007)
FTT_0869 Hypothetical protein – Human, presumed 
type B; mouse
Proteome microarray Unknown Eyles et al. (2007), Sundaresh 
et al. (2007)
FTT_0901 Conserved hypothetical lipoprotein 
(17 kDa major membrane protein 
precursor)
lpnA Human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Unknown Havlasova et al. (2002), Eyles 
et al. (2007), Huntley et al. 
(2007), Janovska et al. (2007a)
FTT_0918 Hypothetical protein – Human type A; 
mouse
2D-Western blot Outer 
membrane
Twine et al. (2006a, Janovska 
et al. (2007b)
FTT_0949 Pseudogene Human, presumed 
type B
Proteome microarray Unknown Sundaresh et al. (2007)
FTT_0956c Hypothetical membrane protein – Human, presumed 
type B; mouse
Proteome microarray Unknown Eyles et al. (2007), Sundaresh 
et al. (2007)
FTT_0975 Hypothetical protein – Human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Unknown Havlasova et al. (2005), Eyles 
et al. (2007), Sundaresh et al. 
(2007)
FTT_0989 Hypothetical protein – Human, presumed 
type B
Proteome microarray Unknown Sundaresh et al. (2007)
FTT_0991 Hypothetical lipoprotein Human, presumed 
type B
Proteome microarray Unknown Sundaresh et al. (2007)
FTT_1043 FKBP-type peptidyl-prolyl cis–trans 
isomerase family protein
– Mouse 2D-Western blot Outer 
Membrane
Twine et al. (2006b)
FTT_1060c 50S ribosomal protein L9 rplI Human, presumed 
type B; mouse
2D-Western blot Cytoplasmic Havlasova et al. (2002, 2005), 
Twine et al. (2006b, 2010)
FTT_1097 Hypothetical protein – Mouse Proteome microarray Unknown Eyles et al. (2007)
(Continued)
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FTT_0280 Major facilitator superfamily (MFS) 
transport protein
Human, presumed 
type B
Proteome microarray Cyt mem Sundaresh et al. (2007)
FTT_0296 Pyrrolidone-carboxylate peptidase pcp Mouse 2D-Western blot/
proteome microarray
Unknown Havlasova et al. (2005), Eyles 
et al. (2007)
FTT_0313 30S ribosomal protein S2 rpsB Mouse 2D-Western blot Unknown Twine et al. (2006b)
FTT_0314 Protein chain elongation factor EF-Ts tsf Mouse 2D-Western blot/
proteome microarray
Cytoplasmic Havlasova et al. (2005), Twine 
et al. (2006a,b), Eyles et al. 
(2007)
FTT_0323 Elongation factor G fusA Mouse 2D-Western blot Cytoplasmic Twine et al. (2006b, 2010)
FTT_0342 30S ribosomal protein S5 rpsE Mouse 2D-Western blot Unknown Twine et al. (2006b)
FTT_0350 DNA-directed RNA polymerase rpoA1 Mouse 2D-Western blot Cytoplasmic Twine et al. (2006a, 2010)
FTT_0356 Heat shock protein htpG Human, presumed 
type B; mouse
2D-Western blot Cytoplasmic Havlasova et al. (2005), Twine 
et al. (2006b), Janovska et al. 
(2007a)
FTT_0373c Nucleoside diphosphate kinase ndk Mouse 2D-Western blot Cytoplasmic Havlasova et al. (2005), Twine 
et al. (2006b)
FTT_0385 Hypothetical protein – Mouse Proteome microarray Unknown Eyles et al. (2007)
FTT_0394 Hypothetical protein Human, presumed 
type B
2D-Western blot Unknown Havlasova et al. (2002)
FTT_0407 Glycine cleavage complex protein T gcvT Human, presumed 
type B; mouse
2D-Western blot Cytoplasmic Havlasova et al. (2002, 2005)
FTT_0448c Glutaminyl-tRNA synthetase glnS Mouse 2D-Western blot Cytoplasmic Twine et al. (2006b)
FTT_0471 3-Dehydroquinate dehydratase aroD Human, presumed 
type B
2D-Western blot Cytoplasmic Havlasova et al. (2002)
FTT_0472 Acetyl-CoA carboxylase, biotin  
carboxyl carrier protein subunit
accB Human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Unknown Havlasova et al. (2002), Twine 
et al. (2006b, 2010), Eyles et al. 
(2007), Janovska et al. (2007a), 
Sundaresh et al. (2007)
FTT_0473 Acetyl-CoA carboxylase, biotin 
carboxylase subunit
accC Mouse 2D-Western blot Cytoplasmic Havlasova et al. (2005)
FTT_0479 PerM family Human, presumed 
type B
Proteome microarray Cytoplasmic 
membrane
Sundaresh et al. (2007)
FTT_0503 Succinyl-CoA synthetase sucD Mouse 2D-Western blot Cytoplasmic Havlasova et al. (2005), Twine 
et al. (2006b)
FTT_0504c Succinyl-CoA synthetase subunit beta Human type A 2D-Western blot Cytoplasmic Janovska et al. (2007b)
FTT_0510 DNA gyrase subunit B Mouse 2D-Western blot Cytoplasmic Twine et al. (2010)
FTT_0511 Pyridoxine/pyridoxal 5-phosphate 
biosynthesis protein
– Mouse 2D-Western blot Cytoplasmic Twine et al. (2006a, 2010)
FTT_0535c Malate dehydrogenase mdh Mouse 2D-Western blot Cytoplasmic Havlasova et al. (2005)
FTT_0557 lemA-like protein Human, presumed 
type B
2D-Western blot Unknown Janovska et al. (2007a)
FTT_0580 Hypothetical protein Mouse 2D-Western blot Cytoplasmic Twine et al. (2010)
FTT_0583 Outer membrane associated protein fopA Human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Outer 
membrane
Havlasova et al. (2005), Twine 
et al. (2006a,b, 2010), Eyles 
et al. (2007), Huntley et al. 
(2007), Janovska et al. (2007a)
FTT_0614 Apolipoprotein N-acyltransferase Human, presumed 
type B
Proteome microarray Cytoplasmic 
mem
Sundaresh et al. (2007)
FTT_0627 DNA binding protein hupB Human, presumed 
type B
2D-Western blot Unknown Havlasova et al. (2002), 
Janovska et al. (2007a)
(Continued)
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FTT_1103 Conserved hypothetical lipoprotein – Human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Unknown Twine et al. (2006b, 2010), 
Eyles et al. (2007), Janovska 
et al. (2007a)
FTT_1115 Preprotein translocase, subunit D, 
membrane protein
secD Mouse Proteome microarray Cytoplasmic 
membrane
Eyles et al. (2007)
FTT_1116 Preprotein translocase family protein yajC Human, presumed 
type B; mouse
Proteome microarray Unknown Eyles et al. (2007), Sundaresh 
et al. (2007)
FTT_1125 D-methionine binding transport  
protein, ABC transporter, membrane 
and periplasmic protein
metIQ Mouse Proteome microarray Cytoplasmic 
membrane
Eyles et al. (2007)
FTT_1156c Type IV pilin multimeric outer 
membrane 
Mouse 2D-Western Blot Outer 
membrane
Huntley et al. (2007), Twine 
et al. (2010)
FTT_1163 Hypothetical membrane protein – Human, presumed 
type B; mouse
Proteome microarray Cytoplasmic 
membrane
Eyles et al. (2007), Sundaresh 
et al. (2007)
FTT_1201c Oxidoreductase – Human, presumed 
type B; mouse
2D-Western blot Cytoplasmic Havlasova et al. (2002, 2005)
FTT_1236 Hypothetical protein Mouse Proteome microarray Unknown Eyles et al. (2007)
FTT_1239 Hypothetical membrane protein Human, presumed 
type B
Proteome microarray Cyt mem Sundaresh et al. (2007)
FTT_1269c Chaperone protein (heat shock  
protein family 70 protein)
dnaK Human type A; 
human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Periplasmic 
space
Havlasova et al. (2002, 2005), 
Twine et al. (2006a,b, 2010), 
Eyles et al. (2007), Janovska 
et al. (2007a,b), Sundaresh 
et al. (2007)
FTT_1270c Chaperone protein grpE Mouse 2D-Western blot Cytoplasmic Havlasova et al. (2005)
FTT_1271 Membrane-bound lytic murein 
transglycosylase A
mltA Mouse Proteome microarray Unknown Eyles et al. (2007)
FTT_1281c Sigma 54 modulation protein yhbH Mouse 2D-Western blot Cytoplasmic Havlasova et al. (2005)
FTT_1303c Hypothetical protein Mouse; human, 
presumed type B
2D-Western blot/
proteome microarray
Unknown Sundaresh et al. (2007), Twine 
et al. (2010)
FTT_1313c Transcriptional elongation factor greA Mouse 2D-Western blot Cytoplasmic Twine et al. (2006b)
FTT_1314c Type IV pili fiber building block  
protein
Human, presumed 
type B; mouse
Proteome microarray Unknown Eyles et al. (2007), Sundaresh 
et al. (2007)
FTT_1317c Inosine-5′-monophosphate 
dehydrogenase
Human, presumed 
type B
2D-Western blot Unknown Janovska et al. (2007a)
FTT_1333 Hypothetical protein Human, presumed 
type B
Proteome microarray Unknown Sundaresh et al. (2007)
FTT_1345 Hypothetical protein pdpB Mouse 2D-Western blot Outer 
Membrane
Havlasova et al. (2002)
FTT_1357/1712 Intracellular growth locus, subunit C iglC Human, presumed 
type B; mouse
2D-Western blot Unknown Havlasova et al. (2002, 2005), 
Twine et al. (2006a)
FTT_1358/1713 Intracellular growth locus, subunit B iglB Human, type A; 
mouse
2D-Western blot/
proteome microarray
Unknown Eyles et al. (2007), Twine et al. 
(2010)
FTT_1368c Glyceraldehyde-3-phosphate 
dehydrogenase
gapA Mouse 2D-Western blot Cytoplasmic Havlasova et al. (2005)
FTT_1369 Transketolase tktA Mouse 2D-Western blot Unknown
FTT_1373 3-Oxoacyl-[acyl-carrier-protein] 
synthase III
Mouse 2D-Western blot Unknown Twine et al. (2010)
FTT_1374 Malonyl CoA acyl carrier protein fabD Mouse 2D-Western blot Cytoplasmic Havlasova et al. (2005), Twine 
et al. (2010)
FTT_1376 Acyl carrier protein acpP Mouse 2D-Western blot Cytoplasmic Twine et al. (2006b)
(Continued)
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FTT_1389 3-Methyl-2-oxobutanoate 
hydroxymethyl-transferase
Mouse 2D-Western blot Unknown Twine et al. (2010)
FTT_1390 Pantoate-beta-alanine ligase panC Mouse 2D-Western blot Cytoplasmic Twine et al. (2006b)
FTT_1402c Hypothetical protein Human, presumed 
type B
2D-Western blot Unknown Janovska et al. (2007a)
FTT_1406c Hypothetical protein – Mouse Proteome microarray Unknown Eyles et al. (2007)
FTT_1416c Hypothetical lipoprotein – Mouse Proteome microarray Unknown Eyles et al. (2007)
FTT_1441 Hypothetical protein – Human, presumed 
type B; mouse
2D-Western blot Cytoplasmic Havlasova et al. (2005), Janovska 
et al. (2007a), Twine et al. (2010)
FTT_1444 Exopolyphosphatase ppx Mouse Proteome microarray Cytoplasmic 
membrane
Eyles et al. (2007)
FTT_1460 UDP-glucose/GDP mannose 
dehydrogenase
wbtE Mouse 2D-Western blot Cytoplasmic Twine et al. (2006b)
FTT_1483c Dihydrolipoamide dehydrogenase Human, presumed 
type B
2D-Western blot Cytoplasmic Janovska et al. (2007a)
FTT_1484c Pyruvate dehydrogenase, E2 
component 
aceF Human, type A; 
human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Cytoplasmic 
membrane
Eyles et al. (2007), Janovska 
et al. (2007a,b), Sundaresh 
et al. (2007), Twine et al. (2010)
FTT_1485c Pyruvate dehydrogenase, subunit E1 Human, type A 2D-Western blot Cytoplasmic Janovska et al. (2007b)
FTT_1498 Acetyl-coenzyme A carboxylase 
carboxyl transferase subunit alpha
Human, presumed 
type B; mouse
2D-Western blot Unknown Janovska et al. (2007a), 
Havlasova et al. (2005)
FTT_1510 Aromatic amino acid transporter of  
the HAAAP family
Human, presumed 
type B
Proteome microarray Cytoplasmic 
membrane
Sundaresh et al. (2007)
FTT_1526 Isocitrate dehydrogenase idh Human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Unknown Havlasova et al. (2005), Eyles 
et al. (2007), Janovska et al. 
(2007a)
FTT_1530 Fusion product of 3-hydroxyacyl-CoA 
dehydrogenase and acyl-CoA-binding 
protein
fadB/ 
acbP
Mouse 2D-Western blot/
proteome microarray
Cytoplasmic Eyles et al. (2007), Twine et al. 
(2010)
FTT_1531 3-Ketoacyl-CoA thiolase Human, presumed 
type B
2D-Western blot Cytoplasmic Janovska et al. (2007a)
FTT_1533 Part of pseudogene of a sugar 
transport protein
– Mouse Proteome microarray – Eyles et al. (2007)
FTT_1539c Hypothetical protein – Human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Unknown Havlasova et al. (2005), Twine 
et al. (2006b), Eyles et al. 
(2007), Janovska et al. (2007a)
FTT_1540c Hypothetical protein – Human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Unknown Eyles et al. (2007), Sundaresh 
et al. (2007), Twine et al. (2010)
FTT_1557c Two component response regulator – Mouse 2D-Western blot Cytoplasmic Havlasova et al. (2005)
FTT_1572c Outer membrane protein OmpH oomph Mouse 2D-Western blot/
proteome microarray
Unknown Havlasova et al. (2005), Eyles 
et al. (2007)
FTT_1591 Lipoprotein Human, presumed 
type B
2D-Western blot Unknown Janovska et al. (2007a)
FTT_1569c UDP-N-acetylglucosamine 
acyltransferase
lpxA Mouse 2D-Western blot Cytoplasmic Twine et al. (2006b)
FTT_1610 Pseudogene Human, presumed 
type B
Proteome microarray Unknown Sundaresh et al. (2007)
FTT_1616 Cysteinyl tRNA synthetase cysS Mouse 2D-Western blot Unknown Twine et al. (2006b)
FTT_1676 Hypothetical membrane protein – Human, type A; 
human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Unknown Eyles et al. (2007), Janovska 
et al. (2007a,b)
(Continued)
Table 3 | Continued
Locus tag Protein name Gene Reactivity sera1 Screening method2 PSORT3 Reference
Frontiers in Microbiology | Cellular and Infection Microbiology  January 2011 | Volume 1 | Article 143 | 14
Kilmury and Twine Francisella proteomics and immunoproteomics
FIGuRE 2 | Venn diagram showing the intersection of immunoreactive 
proteins observed to be reactive with sera from LVS vaccinated and 
protected BALB/c mice and LVS vaccinated and unprotected C57/BL6 mice 
(Twine et al., 2010). Left hand side lists immunoreactive proteins only observed 
to be reactive with sera from LVS vaccinated BALB/c mice, right hand side 
shows proteins only reactive with sera from C57/BL6 mice.
FTT_1695 Chaperone protein, groES groES Human, presumed 
type B; mouse
2D-Western blot Cytoplasmic Havlasova et al. (2002, 2005)
FTT_1696 Chaperone protein, groEL groEL Human, presumed 
type B; mouse
2D-Western blot/
proteome microarray
Cytoplasmic Havlasova et al. (2002, 2005), 
Twine et al. (2006a,b, 2010), 
Eyles et al. (2007), Huntley 
et al. (2007), Janovska et al. 
(2007a), Sundaresh et al. (2007)
FTT_1702 Hypothetical protein Human, presumed 
type B
2D-Western blot Unknown Janovska et al. (2007a)
FTT_1712c Intracellular growth locus, subunit C iglC Human, presumed 
type B
2D-Western blot Unknown Janovska et al. (2007a)
FTT_1713c Intracellular growth locus, subunit B iglB Human, type A 2D-Western blot Unknown Janovska et al. (2007b)
FTT_1714c Intracellular growth locus, subunit A iglA Human, presumed 
type B
2D-Western blot Cytoplasmic Janovska et al. (2007a)
FTT_1724 Outer membrane protein tolC 
precursor
tolC Human, presumed 
type B; mouse
Proteome microarray Outer 
Membrane
Eyles et al. (2007), Sundaresh 
et al. (2007)
FTT_1747 Outer membrane protein – Mouse 2D-Western blot/
proteome microarray
Unknown Twine et al. (2006b), Eyles et al. 
(2007)
FTT_1749 Preprotein translocase, subunit B, 
chaperonin protein
Human, presumed 
type B
2D-Western blot Unknown Janovska et al. (2007a)
FTT_1752 Single stranded binding protein ssb Mouse 2D-Western blot Unknown Havlasova et al. (2005)
FTT_1764c Ferredoxin Mouse 2D-Western blot Cytoplasmic Twine et al. (2006b)
FTT_1769 ClpB clpB Human, presumed 
type B; mouse
2D-Western blot Inner 
membrane
Havlasova et al. (2005), 
Janovska et al. (2007a), Twine 
et al. (2010)
FTT_1775c Voltage-gated ClC-type chloride 
channel clcA
clcA Human, presumed 
type B
Proteome microarray Cytoplasmic 
membrane
Sundaresh et al. (2007)
FTT_1778c Hypothetical membrane protein – Mouse 2D-Western blot/
proteome microarray
Unknown Twine et al. (2006b, 2010), 
Eyles et al. (2007)
1Whether protein was reactive with sera from human infected with type A or type B strains of F. tularensis, or vaccinated mice.
2Method by which protein immunoreactivity was detected.
3Predicted protein subcellular location, using PSORT1b algorithm (Nakai and Horton, 1999; Gardy et al., 2003; Rey et al., 2005).
Table 3 | Continued
Locus tag Protein name Gene Reactivity sera1 Screening method2 PSORT3 Reference
www.frontiersin.org January 2011 | Volume 1 | Article 143 | 15
Kilmury and Twine Francisella proteomics and immunoproteomics
proteome microarray to determine the repertoire of antibodies 
generated in response to vaccination of mice with killed LVS and 
adjuvants. Overall, the murine antibody response was limited to a 
small subset of antigens within the total SCHU S4 proteome, 48 in 
total (Table 3). Of these, 11 of the top 12 immunoreactive proteins 
had previously been identified from studies using 2D-Western blot-
ting approach. Interestingly, the study observed few differences in 
the profile of immunoreactive proteins generated in response to 
vaccination of mice with (1) viable LVS or (2) killed LVS combined 
with ISCOMs or (3) killed LVS combined with ISCOMs and CpG 
(Eyles et al., 2007; Table 3). This suggests that combining killed 
LVS with adjuvant may stimulate the humoral immune system 
similarly to live LVS. Killed LVS without any adjuvant produced a 
profile similar to killed LVS in alum or CpG, but the antibody titers 
were lower and reactive against just eight antigens. Overall, the data 
presented showed that killed LVS with a Th-1 promoting adjuvant 
(e.g., ISCOMS or CpG) confers protection against ID challenge with 
virulent type B strains and some protection against SCHU S4 chal-
lenge. Comparing the immunoreactive profiles of sera from mice 
vaccinated with the various preparations, it is interesting to note 
that the proteins FTT_1296, and FTT_0119 were reactive with sera 
from mice immunized with viable LVS, and killed LVS combined 
with ISCOMS or ISCOMS and CPG, perhaps suggesting that these 
antigens might be indicative of successful protection against chal-
lenge with virulent type B strains. In addition, some antigens, for 
example FTT_1696, and FTT_1484 were reactive in all live and 
killed LVS preparations and are likely not predictive of protective 
immunity in this case (Eyles et al., 2007).
Combined, the murine immunoproteomics studies have raised 
the possibility of using seroconversion to a particular subset of 
antigens of LVS as surrogates of or correlates of protection. The 
most challenging task in this regard is demonstrating that findings 
in mice are applicable to humans.
ImmunoproteomIcs of human tularemIa
The relative rarity of natural cases of type A tularemia have until 
recently, hampered the investigation of the humoral immune 
response in humans, including immunoproteomic studies. At the 
time of writing, only two studies describe the reactivity of human sera 
after type A infections, the first using a 2D-Western blotting approach 
(Janovska et al., 2007b) and the second, using a proteome microarray 
to screen a large number of sera (Sundaresh et al., 2007). The first 
study screened sera from a laboratory worker accidentally infected 
with type A strain SCHU S4 (Janovska et al., 2007b). The subject 
suffered oculoglandular tularemia, which recurred 17 months after 
the original infection. Sera collected 2, 5, and 16 years after infection, 
were used to screen a membrane enriched subproteome of LVS, and 
10 immunoreactive proteins were identified (Table 3). Interestingly, 
the intensity of immunoreactivity toward these proteins showed no 
apparent decline over the three serum samples screened, with the 
exception of a loss of reactivity toward the hypothetical protein 
FTT_0918, which was only observed to be reactive with sera collected 
2 years post-infection (Janovska et al., 2007b). This is in contrast 
with studies of patients who have recovered from type B infections. 
In such studies, a decline in overall antibody titers has been observed 
in the 25-year period post-infection (Ericsson et al., 1994a). Overall, 
only 3 of the 10 immunoreactive proteins observed in the study of 
the infected laboratory worker; intracellular growth locus, subunit B 
(FTT_1713c), pyruvate dehydrogenase, E1 component (FTT_1485c), 
and Succinyl-CoA synthetase subunit beta (FTT_0504c), have not 
thus far been observed to be reactive with sera from vaccinated mice, 
or convalescent sera from type B infected individuals.
The Francisella proteome microarray was used to screen sera 
from patients recovering from either type A or B Francisella infec-
tions contracted in North America (Sundaresh et al., 2007). Of the 
46 sera from infected individuals, 10 were from confirmed cases 
of type A tularemia and 5 from confirmed type B tularemia. The 
immunodominant proteins were reported in this study (Table 3), 
and of the top 10 antigens, many have also been reported in immu-
noproteomics studies carried out with sera from LVS infected mice. 
In addition, a sufficient number of sera were screened, that a com-
parison of the repertoire of proteins reactive with sera from patients 
recovering from infection with different subtypes of Francisella 
and different routes of infection could be carried out. For example, 
authors noted that the protein FTT_1484 was more reactive with 
sera from patients suffering with ulceroglandular tularemia, com-
pared with the sera from patients with the pneumonic form of the 
disease. Also, the protein FTT_0975 is more reactive with sera from 
type B infected individuals compared to type A infected individuals, 
although the authors note that a rigorous statistical assessment of 
these observations was outside the scope of their study.
Immunoproteomics was used to survey the repertoire of 
immunoreactive proteins with sera of human type B convales-
cents (Janovska et al., 2007a). This study described the reactivity 
of serum collected from nine tularemia patients with a membrane 
enriched fraction of LVS, and the proteome of LVS grown under 
oxidative stress conditions. Details of the type of tularemia, or the 
time after diagnosis that sera were drawn were not provided, pre-
sumably due to patient confidentiality. The immunoproteomics 
profiles of patient sera showed marked heterogeneity, with a limited 
number of commonly reactive proteins observed. This variability 
in profile of immunoreactive proteins has also been noted with 
human patient sera from other diseases, such as Helicobacter pylori 
(Kimmel et al., 2000; Krah et al., 2004). Of the 35 immunoreac-
tive proteins identified (Table 3), a small proportion were reac-
tive with the majority of sera screened, as illustrated in Figure 3; 
the antigens pyruvate dehydrogenase E2 component (FTT_1484), 
dihydrolipoamide succinyltransferase component of 2-oxogluta-
rate dehydrogenase component (FTT_077), chaperonin protein 
GroEL (FTT_1696), acetyl-CoA carboxylase (FTT_0472), hypo-
thetical protein (FTT_1441) and 50S ribosomal protein L7/L12 
(FTT_0143) were reactive with six or more of the sera screened. 
Of note, although the protein FTT_0077 was reactive with eight of 
the nine patient sera screened, no single protein was observed to 
be reactive with all of the patient sera in this study.
characterIstIcs of the total reported repertoIre of 
ImmunoreactIve proteIns
Table 3 summarizes the antigenic proteins reported in recent 
immunoproteomics studies. Commonalities in the identified pro-
teins across various studies can be noted and will be reviewed here, 
but comprehensive comparisons of the immunoproteomics data 
are hampered by distinct differences in the studies, including the 
immunoproteomics approach used, the host organism, the bacterial 
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Figure 3 | Frequency with which immunoreactive proteins from LVS 
proteome were observed to react with sera from patients recovering from 
type B Francisella tularensis infections. FTT_number refers to the locus tag of the 
ORF within the SCHU S4 genome sequence. *Indicates that sera reacted with 
isoforms of the same protein, shown is the highest observed frequency of reactivity. 
These data were originally reported by and tabulated in Havlasova et al. (2002).
strain, source of strain, or treatment of the strain used for either 
infection or immunization, and the bacterial strain or subproteome 
used as the antigen. In total, 143 antigenic proteins were identified 
in 11 separate studies. Thirteen of these proteins were reported to 
be immunoreactive in half of the studies (FTT_1696, FTT_1269c, 
FTT_1696, FTT_0077, FTT_0137, FTT_0472, FTT_0583, 
FTT_0721c, FTT_0143, FTT_1103, FTT_0863, FTT_1484c). Of 
these proteins, FTT_2369c, FTT_1696, FTT_0583, FTT_0721c, and 
FTT_1103 were also noted to be components of LVS and SCHU S4 
outer membrane preparations (Huntley et al., 2007).
Examining the immunoreactive proteins by Clusters of 
Orthologous groups, antigenic proteins are observed to belong 
to a diverse array of functional categories (Figure 4), but pro-
teins involved in energy production, chaperonins and proteins of 
unknown function were highly represented. Using the PSORT1b 
algorithm as a predictor of protein localization within the bacterial 
cell (Nakai and Horton, 1999; Gardy et al., 2003; Rey et al., 2005), 
the vast majority of the identified immunoreactive proteins were 
predicted to be cytoplasmic (44%) or of unknown location (42%; 
Figure 4). This is in contrast with the results from proteome micro-
array studies alone, where half of the identified proteins were clas-
sified as membrane or surface associated (Eyles et al., 2007). This is 
likely a reflection of the number of immunoproteomics studies car-
ried out using gel-based techniques, which are well documented to 
underrepresent very large or hydrophobic membrane proteins. The 
high proportion of proteins that have no predicted location reflects 
the high number of hypothetical proteins within the Francisella 
proteome, which have little or no homology to known proteins.
Although underrepresented in the entire dataset, membrane 
proteins are of some interest in immunoproteomics studies. 
Exposed on the outer bacterial surface, OMPs are generally involved 
in pathogen evasion of the host, intracellular survival and immune 
evasion. Characterization of LVS outer membrane proteins, listed 
12 OMPs (Huntley et al., 2008). Of these, 10 were observed to be 
immunoreactive with sera from either murine or human immu-
noproteomics studies. This LVS outer membrane preparation has 
been reported to show potential as an acellular vaccine; vaccination 
of mice with LVS native OMPs resulted in 50% survival rate over 
20 days post-challenge with SCHU S4 (Huntley et al., 2008). Also 
observed was a three log reduction in bacterial burdens in the liver 
and spleen compared with sham vaccinated animals. This clearly 
suggests a link between OMPs and protective immunity.
Of the OMPs identified by a proteomics approach (Huntley 
et al., 2008), some have been identified previously, with demon-
strated immunoreactivity. For example, the first presumed F. tula-
rensis OMP was a 43-kDa protein identified by probing lithium 
chloride extracts of bacteria with antisera collected from individuals 
involved in an outbreak of tularemia in Norway (Ericsson et al., 
1994a). This protein was named FopA, for Francisella outer mem-
brane protein. Two separate vaccine trials demonstrated that FopA 
was not protective against type A F. tularensis or LVS challenge, 
despite its induction of antibodies (Fulop et al., 1995, 1996). FopA 
was observed to be immunoreactive in many of the immunopro-
teomics studies described herein.
The second reported presumed F. tularensis OMP was a 17-kDa 
T lymphocyte-reactive protein originally identified from an 
N-lauroylsarcosinate-insoluble protein preparation; this 17-kDa 
polypeptide was later named TUL4 (Sjostedt et al., 1990). TUL4 is 
conserved in F. tularensis and F. novicida strains, whereas an immu-
nologically related protein is present in F. philomiragia. Additional 
studies confirmed the ability of TUL4 to stimulate lymphocyte pro-
liferation, primarily CD4 T cells, and noted marked production of 
interleukin-2 (IL-2) and gamma interferon (IFN-γ) in response to 
TUL4 (Sjostedt et al., 1992a,b; Golovliov et al., 1995; Valentino et al., 
2009). Initial [3H]palmitate radiolabeling and detergent extrac-
tion of F. tularensis suggested that TUL4 was an integral mem-
brane lipoprotein (LP; Sjostedt et al., 1991). Bacterial lipoproteins 
have an inflammatory capacity and ability to stimulate cells of the 
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FIGuRE 4 | Basic bioinformatic characterization of the repertoire of reported 
Francisella immunoreactive proteins. Graphical representation of (A) clusters of 
orthologous groups (COGs) and (B) predicted subcellular location using PSORT 
algorithm, for total reported immunoreactive proteins from Francisella 
immunoproteomics studies. Taken from the reported immunoreactive proteins 
listed in Table 3.
innate immune system via TLR2 (Thakran et al., 2008). Although 
the lipoprotein TUL4 is not essential for virulence of F. tularensis 
(Forestal et al., 2008), amino acids 86–99 of the protein were iden-
tified as an immunodominant epitope of CD4T cells in B6 mice 
(Valentino et al., 2009). A recent study showed that the hypothetical 
lipoprotein, denoted FTT_1416c or FTL0645 of LVS, was enriched 
in a sarkosyl membrane extraction. Expression of the equivalent 
recombinant protein in E. coli produced a lipoprotein that was able 
to activate TLR2 and induce an immunogenic response in mice 
(Parra et al., 2009). The lipoprotein was also shown to be immu-
noreactive with immune sera from mice in other work.
Chaperonin proteins feature frequently in tularemia immu-
noproteomics studies. The chaperonin protein DnaK and GroEL 
(Cpn60) were reactive with the vast majority of sera screened. 
Chaperonins, also known as heat shock proteins are among the most 
highly conserved protein families in nature and are expressed in 
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FIGuRE 5 | Venn diagram showing the intersection of immunoreactive proteins observed to be reactive with sera from LVS vaccinated mice and human 
convalescent. From Table 3.
both prokaryotes and eukaryotes (Ranford and Henderson, 2002). 
These proteins facilitate the non-covalent assembly of proteins and 
when cells are exposed to stress conditions, such as temperature or 
pH, chaperones protect cellular proteins from aggregation and also 
promote refolding (Stewart et al., 2004). Chaperonins have also been 
observed to be activators of the innate immune system (Kol et al., 
1999; Wallin et al., 2002), in addition to stimulating monocytes, 
macrophages and dendritic cells to produce nitric oxide and a vari-
ety of cytokines (Kol et al., 1999; Wallin et al., 2002). Although most 
heat shock proteins are widely accepted to be cellular proteins some, 
for example GroEL can also be released from cells, and stimulate 
a immune response (Henderson et al., 2006). Other studies have 
reported that GroEL and DnaK of Mycobacterium tuberculosis and 
F. tularensis are located either on the cell surface (Hickey et al., 2009) 
or partition with membrane protein subproteome (Huntley et al., 
2007). GroEL of F. tularensis, has been observed at increased levels 
under conditions of stress (Ericsson et al., 1994b; Twine et al., 2006a) 
and has been detected in the cytosol of host cells infected with the 
bacterium (Lee et al., 2006). It has been suggested that the predomi-
nant source of Francisella chaperonins in the host are derived from 
bacteria that are either extracellular in the blood (Forestal et al., 
2007) or lungs (Bosio et al., 2007) or from bacteria that fail to prolif-
erate in the host environment. GroEL has also been reported to have 
an inflammatory role, stimulating macrophages via TLR4, but not 
human endothelial cells (Noah et al., 2010). In addition, GroEL and 
LPS derived from LVS acted together to elicit a synergistic response 
in macrophages (Noah et al., 2010). Similarly, another Francisella 
heat shock protein, DnaK, has been reported to mediate activation 
of dendritic cells via TLR4 (Ashtekar et al., 2008).
Heat shock proteins (Hsps) have been reported to be dominant 
antigens for the host immune response to various pathogens, and 
have been attempted to be used in subunit vaccines against some 
pathogens (Khan et al., 2009). The potential of Hsps to elicit both 
cell-mediated and humoral immune responses even in the absence 
of exogenous adjuvants (Lowrie et al., 1997; Harmala et al., 2002), 
their requirement in small quantities and ability to elicit memory 
T cell response, make them attractive vaccine candidates against 
infectious disease.
As noted in this article, the relative rarity of naturally occur-
ring human tularemia and the ethical issues with human LVS vac-
cination and challenge studies, means that much of our recent 
knowledge stems from the murine model of tularemia. A signifi-
cant challenge in this regard, is determining whether findings in 
mice are applicable to humans. Reviewing the complement of 
identified immunoreactive proteins listed in Table 3 and also in 
Figure 5, shows the overlap between antigens reactive with both 
murine and human sera. This shows that the 43 antigens have been 
observed to be reactive with LVS vaccinated murine and human 
convalescent sera.
conclusIon
There continues to be a significant focus upon the development 
of efficacious, safe and licensable tularemia vaccines. Acellular or 
subunit vaccines carry far less risk than attenuated live vaccines, but 
there are limited reports of success with subunit tularemia vaccine 
development. The lack of knowledge of both Francisella virulence 
factors, protective antigens and the complex nature of immunity 
to Francisella is inhibiting vaccine development. Further studies 
of the humoral immune response, especially those in other animal 
models of tularemia that will bridge the differences between mice 
and humans, will be required to determine those antigens that can 
be predicted to be protective in humans. This will aid greatly in 
the development of subunit vaccines and selection of antigens for 
incorporation into diagnostic tests.
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